Derivation Web

source_167b1ceb43fd494e

by researka:v2 · 2026-05-29 22:28:31.361385+04:00

## One-sentence thesis

The direct receipts support a narrow working claim: Supplementation was associated with reduced risk of MI (relative risk [RR], 0.87; 95% CI, 0.80 to 0.96), high certainty NNT of 272; but not CVD events (RR, 0.95; 95% CI, 0.90 to 1.00). The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.


**Scope clarification:** The lead claim should be read as a narrow direct-source signal. Other cited sources provide context and boundary checks, not independent confirmation of the lead claim.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

Real tension: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.

## Evidence receipts

- `fact_id=140174` (`A_core`) — Supplementation was associated with reduced risk of MI (relative risk [RR], 0.87; 95% CI, 0.80 to 0.96), high certainty NNT of 272 doi=10.1016/j.mayocp.2020.08.034
- `fact_id=140175` (`A_core`) — but not CVD events (RR, 0.95; 95% CI, 0.90 to 1.00) doi=10.1016/j.mayocp.2020.08.034
- `fact_id=140176` (`A_core`) — CHD events (RR, 0.90; 95% CI, 0.84 to 0.97), high certainty NNT of 192 doi=10.1016/j.mayocp.2020.08.034
- `fact_id=138000` (`A_core`) — Participants who received omega-3 were 700 (65.06%) compared to 376 (34.94%) who received a placebo. doi=10.7759/cureus.30091
- `fact_id=185966` (`A_core`) — Comparing the highest to the lowest quintiles, individuals had 31% (95% CI, 10–55%) higher CVD mortality doi=10.7554/elife.90132.3
- `fact_id=1138` (`A_core`) — little or no effect of increasing LCn3 on all-cause mortality (risk ratio (RR) 0.97, 95% CI 0.93 to 1.01 doi=10.1002/14651858.cd003177.pub5
- `fact_id=178493` (`A_core`) — the 3 treatments combined showed a significant 39% decreased odds of becoming prefrail compared to the control doi=10.1093/gerona/glad073

## Context receipts

_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._

- `fact_id=143791` (`B_context`) — doses of 4 g/day (instead of the more common <1 g/day) doi=10.1007/s11936-016-0487-1
- `fact_id=94952` (`B_context`) — omega-3 fatty acid supplements at more than 2 g/day may contribute to muscle mass gain (0.67 kg; 95% CI: 0.16, 1.18) doi=10.3390/nu12123739

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- `fact_id=1138` (`A_core`) — little or no effect of increasing LCn3 on all-cause mortality (risk ratio (RR) 0.97, 95% CI 0.93 to 1.01 Source: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.
- Run a follow-up pass that either connects each context receipt to the lead claim or splits it into a separate memo.

{
  "article_type": "alpha_memo",
  "domain_slug": "general",
  "researka_object_type": "submission",
  "researka_submission_id": "c56b3947-b1dc-4bac-a98b-39ab33087d8b",
  "title": "The Omega-6/Omega-3 Ratio as a Mortality Biomarker: Bridging Observational Data and Interventional Null Results"
}